Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 20/20 | 0.68 |
| ▸ | PIK3CD | O00329 | 19/20 | 0.68 |
| ▸ | PIK3R1 | P27986 | 19/20 | 0.68 |
| ▸ | PIK3CB | P42338 | 14/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2815274 | 0.92 | PIK3CA (0.67) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL14999989 | 0.85 | PIK3CA (0.79) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL2810449 | 0.84 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL477724 | 0.84 | PIK3CA (0.66) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL14999991 | 0.84 | PIK3CA (0.78) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL1044485 | 0.82 | PIK3CA (0.71) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL908851 | 0.82 | PIK3CA (0.65) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL909806 | 0.81 | PIK3CA (0.77) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL12847347 | 0.81 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3R1PIK3CB | |
| SCHEMBL12847391 | 0.81 | PIK3CA (0.76) | PIK3CAPIK3CDPIK3R1PIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PATHWAY THERAPEUTICS LIMITED (NZ) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249099-A1 | PYRIMIDINYL AND 1,3,5-TRIAZINYL BENZIMIDAZOLE SULFONAMIDES AND THEIR USE IN CANCER THERAPY | PAICS, CCNI, TYMS | PIK3CA 99/4885PIK3CD 499/4885PIK3R1 1213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.